Your browser doesn't support javascript.
loading
Structure of the IFNγ receptor complex guides design of biased agonists.
Mendoza, Juan L; Escalante, Nichole K; Jude, Kevin M; Sotolongo Bellon, Junel; Su, Leon; Horton, Tim M; Tsutsumi, Naotaka; Berardinelli, Steven J; Haltiwanger, Robert S; Piehler, Jacob; Engleman, Edgar G; Garcia, K Christopher.
Afiliação
  • Mendoza JL; Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Escalante NK; Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
  • Jude KM; Institute for Molecular Engineering and Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL, USA.
  • Sotolongo Bellon J; Stanford Blood Center, Palo Alto, CA, USA.
  • Su L; Department of Pathology, School of Medicine, Stanford University, Palo Alto, CA, USA.
  • Horton TM; Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Tsutsumi N; Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
  • Berardinelli SJ; Division of Biophysics, Department of Biology, University of Osnabruck, Osnabruck, Germany.
  • Haltiwanger RS; Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Piehler J; Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
  • Engleman EG; Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Garcia KC; Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
Nature ; 567(7746): 56-60, 2019 03.
Article em En | MEDLINE | ID: mdl-30814731
The cytokine interferon-γ (IFNγ) is a central coordinator of innate and adaptive immunity, but its highly pleiotropic actions have diminished its prospects for use as an immunotherapeutic agent. Here, we took a structure-based approach to decoupling IFNγ pleiotropy. We engineered an affinity-enhanced variant of the ligand-binding chain of the IFNγ receptor IFNγR1, which enabled us to determine the crystal structure of the complete hexameric (2:2:2) IFNγ-IFNγR1-IFNγR2 signalling complex at 3.25 Å resolution. The structure reveals the mechanism underlying deficits in IFNγ responsiveness in mycobacterial disease syndrome resulting from a T168N mutation in IFNγR2, which impairs assembly of the full signalling complex. The topology of the hexameric complex offers a blueprint for engineering IFNγ variants to tune IFNγ receptor signalling output. Unexpectedly, we found that several partial IFNγ agonists exhibited biased gene-expression profiles. These biased agonists retained the ability to induce upregulation of major histocompatibility complex class I antigen expression, but exhibited impaired induction of programmed death-ligand 1 expression in a wide range of human cancer cell lines, offering a route to decoupling immunostimulatory and immunosuppressive functions of IFNγ for therapeutic applications.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Desenho de Fármacos / Interferon gama / Receptores de Interferon Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Desenho de Fármacos / Interferon gama / Receptores de Interferon Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article